Microneedles and ultra-sensitive biomarker analysis in melanoma (IMAGE)
Caption
The team engineered a strategy for monitoring the immunological responses to a newly devised, locally applied immunotherapy against melanoma. The therapy acts locally on tumor lesions by combining non-invasive focused ultrasound (FUS) with the delivery of a previously developed nanoparticle-bound activator of an inflammation-inducing protein known as stimulator of interferon genes (STING). To monitor biomarkers informing about the responsiveness of immune cells to the therapy, first, interstitial skin fluid is sampled with microneedles from the lesions, and then biomarkers contained in it quantified with ultra-sensitive Simoa assays.
Credit
Wyss Institute at Harvard University
Usage Restrictions
None
License
Original content